KRAS and neoplasm: Given the gene mutation of Smad 4 in Panc02 cells, Kras in KrasG12D cells, both Kras and TP53 in UN-KPC-961 and human Panc-1 cells, our findings suggests that ABTB2 may retain its tumor-suppressive potential in the broad context of Kras, TP53, or SMAD4 mutation.